Navigation Links
Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
Date:9/9/2007

HILTON HEAD ISLAND, S.C., Sept. 9 /PRNewswire/ -- At approximately 3:21 PM today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to act as a conduit to provide samples of Global Humanceuticals, Inc's., new extremely effective, safe and stable drug candidate to profit, non-profit, academic, government, non-government, U.S. and foreign institutions, organizations, and corporations, under mutual agreements, contracts or partnerships, to spur theoretical, objective, mechanistic, developmental or clinical research. This unique new chemical entity is referred to as compound NIAID #11039. However, this invention has already received a patent called: Antiviral Composition, U.S. patent number: 6,821,958 on November 23, 2004. The World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

"This gift is intended to extend technology that no one else posses on this planet." Stated Dr. Hershline. "Already, Chinese scientists are very interested." Dr. Hershline hosted Session V at the World Aids Day Conference China Dec 1 to Dec 3, 2006, to initially present data an NIAID #11039. There was, unfortunately, a communication error from the National Institute of Health (NIH of the United States) to Dr. Hershline, which prevented presentation of test results.

The compound has a non-toxic alpha-glucose backbone, obtained from an abundant natural source. The backbone is chemically bi-substituted in a random fashion, by a new reaction. "The substitution groups are different sulfur based viral de-activating groups that work together to provide viral entry inhibition at concentrations of one pico-Molar. This active concentration is equivalent to diluting a 1% solution one million times.

The random substitutions are intended to prevent the virus from escaping de-activation thru mutation. "Global Humanceuticals, Inc.'s NIAID #11039 is the first drug designed to prevent the development of resistance, the biggest nightmare in HIV treatment," stated Dr. Hershline.

"I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467, Hilton Head Is., SC, 29925, by fax: 843-342-5924, phone: 843-342-5900. Direct to Dr. Hershline: 843-683-3683.


'/>"/>
SOURCE Global Humanceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):